Table 1 Variables associated with IgG and neutralizing antibody titers
From: Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
Variable | IgG (aftera V2) | IgG (aftera V3) | IgG ratio V2/V3 | Neutralizing antibodies (aftera V2) | Neutralizing antibodies (aftera V3) | Neutralizing antibodies ratio V2/V3 |
|---|---|---|---|---|---|---|
Total | 3,477 ratio of mean (95% CI) | 1,232 ratio of mean (95% CI) | Ratio of mean (95% CI) | 644 ratio of mean (95% CI) | 692 ratio of mean (95% CI) | Ratio of mean (95% CI) |
Age (years) | ||||||
<60 | 1 | 1 | n/a | 1 | 1 | n/a |
≥60 | 0.70 (0.65–0.75) | 1.03 (0.93–1.13) | 1.47 (1.32–1.62) | 0.61 (0.52–0.72) | 1.13 (0.96–1.33) | 1.86 (1.50–2.30) |
Sex | ||||||
Female | 1 | 1 | n/a | 1 | 1 | n/a |
Male | 0.87 (0.82–0.93) | 0.95 (0.85–1.05) | 1.08 (0.98–1.19) | 0.79 (0.66–0.96) | 0.77 (0.65–0.92) | 0.97 (0.77–1.23) |
Comorbidities | ||||||
BMI < 30 | 1 | 1 | n/a | 1 | 1 | n/a |
BMI ≥ 30 | 1.10 (1.02–1.18) | 1.31 (1.17–1.47) | 1.19 (1.07–1.34) | 0.99 (0.79–1.25) | 1.12 (0.89–1.42) | 1.13 (0.84–1.53) |
No specific comorbidityb | 1 | 1 | n/a | 1 | 1 | n/a |
One specific comorbidityb | 0.88 (0.81–0.95) | 0.93 (0.83–1.04) | 1.05 (0.94–1.17) | 0.98 (0.81–1.20) | 0.98 (0.78–1.22) | 0.99 (0.75–1.31) |
Two or more specific comorbiditiesb | 0.73 (0.61–0.87) | 0.86 (0.69–1.10) | 1.18 (0.92–1.53) | 0.73 (0.54–0.98) | 0.96 (0.69–1.32) | 1.31 (0.88–1.94) |
